interima analysis of phase III Atalante 1 trial of Tedopi meets endpoint in NSCLC but trial on temporary hold.- OSE Immunotherapeutics
OSE Immunotherapeutics announced that the primary endpoint was met in the predefined Step-1 analysis of its Phase III Atalante 1 clinical trial of Tedopi (T-lymphocyte stimulators) in HLA-A2… read more.